Jason Wittes
Stock Analyst at Roth Capital
(2.69)
# 1,911
Out of 5,150 analysts
60
Total ratings
50%
Success rate
4.65%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $9.04 | +342.48% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $381.89 | +19.41% | 11 | May 2, 2025 | |
| ALUR Allurion Technologies | Reiterates: Buy | $16 | $0.76 | +2,008.59% | 2 | Mar 21, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $3.10 | +416.13% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $12.87 | +70.94% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $105.11 | -31.50% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $5.00 | +120.00% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $90.46 | +27.13% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $8.04 | +36.82% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.02 | +880.39% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $100 | $106.41 | -6.02% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.20 | +127.27% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.52 | +1,621.50% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $25.79 | +190.81% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $13.00 | +69.23% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $95.75 | +25.33% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $175.37 | +17.47% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $203.41 | -28.72% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.45 | +20.48% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $13.42 | +1,390.31% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $29.19 | -10.93% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $9.04
Upside: +342.48%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $381.89
Upside: +19.41%
Allurion Technologies
Mar 21, 2025
Reiterates: Buy
Price Target: $16
Current: $0.76
Upside: +2,008.59%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $3.10
Upside: +416.13%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $12.87
Upside: +70.94%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $105.11
Upside: -31.50%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $5.00
Upside: +120.00%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $90.46
Upside: +27.13%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $8.04
Upside: +36.82%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.02
Upside: +880.39%
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $106.41
Upside: -6.02%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $2.20
Upside: +127.27%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.52
Upside: +1,621.50%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $25.79
Upside: +190.81%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $13.00
Upside: +69.23%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $95.75
Upside: +25.33%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $175.37
Upside: +17.47%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $203.41
Upside: -28.72%
Mar 3, 2022
Initiates: Buy
Price Target: $15
Current: $12.45
Upside: +20.48%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $13.42
Upside: +1,390.31%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $29.19
Upside: -10.93%